JN Nova Pharma Inc. has initiated a collaboration with the National Research Council (NRC) pandemic program to expand a healing process for the serious situations observed in COVID-19.
COVID-19 is not “just a respiratory infection”, it is a complex disease that damages several organs, adding the lungs, center, blood vessels and brain. JN Nova Pharma and the NRC team at the Human Health Therapeutic Research Center are jointly developing a multifunctional fusion protein platform healing technique to treat the complex manifestations of COVID-19. The purpose is to save the cell invasion of SARS-Cov2 in these tissues (viral trap) and mitigate the pathology triggered by the host’s reaction to the virus, adding overactivation of the immune formula and pulmonary and central failure. Based on paintings of past joints in the brain disease box, this collaboration will also deal with the severe neurological headaches of COVID-19.
JN Nova Pharma will be a progression spouse for the healing modalities resulting from this project, which will allow its accelerated translation through bioproduction and clinical trials. The first manual healing pathway is expected to begin efficacy and biofabrication testing in September.
JN Nova Pharma executives Dr. John Gillard and Dr. Nathan Yoganathan are experienced biotechnological drug developers. Dr. John Gillard, JN Nova’s chief executive, said they plan to launch the first human trials next year. It is now transparent that there are different susceptibility in patient teams to the severity of the disease and the elucidation of early biomarkers with a threat of headaches is a key step in individualizing the remedy. Above all, we must avoid cytokine storms, resulting in the placement of the ICU and the rescue of the fan. Individualized cure can be achieved by developing a precision medicine technique for coVID-19 remedy, which is our goal, Dr. Gillard said.
We plan to use Canadian production equipment to produce COVID-19 curative products for clinical trials in 2021,” said Dr. Nathan Yoganathan, president and ceo of JN Nova Pharma Inc., as well as ensuring a sustainable source of our portfolio of long-term projects for acute respiratory distress treatments for Canada and the rest of the world.
Learn more about NRC’s Pandemic Response Challenge program.
Dr. John Gillard Media [email protected]
Dr. T. Nathan Yoganathan [email protected]
Mandatory cookies are surely for the proper functioning of the site. This category includes only cookies that provide the fundamental capacity and security features of the website. These cookies do not purchase any non-public information.